Chua K C, Kroetz D L
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Clin Pharmacol Ther. 2017 Apr;101(4):450-452. doi: 10.1002/cpt.590. Epub 2017 Feb 22.
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity experienced in 30-40% of patients undergoing treatment with various chemotherapeutics, including taxanes, vinca alkaloids, epothilones, proteasome inhibitors, and thalidomide. Importantly, CIPN significantly affects a patient's quality of life. Recent genetic association studies are enhancing our understanding of CIPN pathophysiology and serve as a foundation for identification of genetic biomarkers to predict toxicity risk and for the development of novel strategies for prevention and treatment.
化疗引起的周围神经病变(CIPN)是一种常见的剂量限制性毒性反应,30%-40%接受包括紫杉烷类、长春花生物碱、埃坡霉素、蛋白酶体抑制剂和沙利度胺等各种化疗药物治疗的患者会出现这种情况。重要的是,CIPN会显著影响患者的生活质量。最近的基因关联研究正在加深我们对CIPN病理生理学的理解,并为识别预测毒性风险的基因生物标志物以及开发预防和治疗新策略奠定基础。